Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.
Kobayashi T, Iwama S, Yamagami A, Izuchi T, Suzuki K, Otake K, Yasuda Y, Ando M, Onoue T, Miyata T, Sugiyama M, Hagiwara D, Suga H, Banno R, Hase T, Nishio N, Mori S, Shimokata T, Sano T, Niimi K, Yoshikawa N, Akamatsu S, Ando Y, Akiyama M, Sone M, Ishii M, Arima H.
Kobayashi T, et al. Among authors: sugiyama m.
Cancer Immunol Immunother. 2024 Jun 4;73(8):146. doi: 10.1007/s00262-024-03733-2.
Cancer Immunol Immunother. 2024.
PMID: 38833157
Free PMC article.